Nuts and seeds consumption and risk of cardiovascular disease, type 2 diabetes and their risk factors: a systematic review and meta-analysis

• Published in: Food & nutrition research Vol. 67; pp. 1 - 33
• Main Authors: Arnesen, Erik Kristoffer, Thorisdottir, Birna, Bärebring, Linnea, Söderlund, Fredrik, Nwaru, Bright I, Spielau, Ulrike, Dierkes, Jutta, Ramel, Alfons, Lamberg-Allardt, Christel, Åkesson, Agneta
• Format: Journal Article
• Language: English
• Published: Sweden Open Academia 2023; Swedish Nutrition Foundation
• Subjects: atherosclerosis; cardiovascular disease; diabetes mellitus type 2; Medicin och hälsovetenskap; meta-analysis; nuts; Review; systematic review; atherosclerosis; meta-analysis; cardiovascular disease; diabetes mellitus type 2; systematic review; nuts
• ISSN: 1654-661X; 1654-661X
• DOI: 10.29219/fnr.v67.8961

We aimed to systematically review studies and evaluate the strength of the evidence on nuts/seeds consumption and cardiometabolic diseases and their risk factors among adults.
A protocol was pre-registered in PROSPERO (CRD42021270554). We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials and Scopus up to September 20, 2021 for prospective cohort studies and ≥12-week randomized controlled trials (RCTs). Main outcomes were cardiovascular disease (CVD), coronary heart disease (CHD), stroke and type 2 diabetes (T2D), secondary total-/low density lipoprotein (LDL)-cholesterol, blood pressure and glycaemic markers. Data extraction and risk of bias (RoB) assessments (using RoB 2.0 and RoB-NObS) were performed in duplicate. Effect sizes were pooled using random-effects meta-analyses and expressed as relative risk (RR) or weighted mean differences with 95% confidence intervals (CI); heterogeneity quantified as
. One-stage dose-response analyses assessed the linear and non-linear associations with CVD, CHD, stroke and T2D. The strength of evidence was classified per the World Cancer Research Fund criteria.
After screening 23,244 references, we included 42 papers from cohort studies (28 unique cohorts, 1,890,573 participants) and 18 RCTs (2,266 participants). In the cohorts, mainly populations with low consumption, high versus low total nuts/seeds consumption was inversely associated with total CVD (RR 0.81; 95% CI 0.75, 0.86;
= 67%), CVD mortality (0.77; 0.72, 0.82;
= 59.3%), CHD (0.82; 0.76, 0.89;
= 64%), CHD mortality (0.75; 0.65, 0.87;
= 66.9%) and non-fatal CHD (0.85; 0.75, 0.96;
= 62.2%). According to the non-linear dose-response analyses, consumption of 30 g/day of total nuts/seeds was associated with RRs of similar magnitude. For stroke and T2D the summary RR for high versus low intake was 0.91 (95% CI 0.85, 0.97;
= 24.8%) and 0.95 (0.75, 1.21;
= 82.2%). Intake of nuts (median ~50 g/day) lowered total (-0.15 mmol/L; -0.22, -0.08;
= 31.2%) and LDL-cholesterol (-0.13 mmol/L; -0.21, -0.05;
= 68.6%), but not blood pressure. Findings on fasting glucose, HbA1c and insulin resistance were conflicting. The results were robust to sensitivity and subgroup analyses. We rated the associations between nuts/seeds and both CVD and CHD as
. There was limited but
evidence for no association with stroke. No conclusion could be made for T2D.
There is a probable relationship between consumption of nuts/seeds and lower risk of CVD, mostly driven by CHD, possibly in part through effects on blood lipids. More research on stroke and T2D may affect the conclusions. The evidence of specific nuts should be further investigated.